Pazopanib
- Generic Name
- Pazopanib
- Brand Names
- Votrient
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23N7O2S
- CAS Number
- 444731-52-6
- Unique Ingredient Identifier
- 7RN5DR86CK
- Background
Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.
- Indication
Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)
- Associated Conditions
- Advanced Renal Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Thyroid cancer
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2020-08-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 57
- Registration Number
- NCT01956669
- Locations
- 🇪🇸
Novartis Investigative Site, Madrid, Spain
Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
- Conditions
- Brain NeoplasmsGlioblastomaGlioblastoma MultiformeGliosarcomaCentral Nervous System Neoplasms
- Interventions
- First Posted Date
- 2013-08-29
- Last Posted Date
- 2020-11-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 35
- Registration Number
- NCT01931098
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
PAZOPANIB Efficacy and Tolerance in Desmoids Tumors
- First Posted Date
- 2013-06-12
- Last Posted Date
- 2021-03-05
- Lead Sponsor
- Institut Bergonié
- Target Recruit Count
- 72
- Registration Number
- NCT01876082
- Locations
- 🇫🇷
Institut Bergonié, Bordeaux, Aquitaine, France
A Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma
- First Posted Date
- 2013-05-24
- Last Posted Date
- 2017-08-21
- Lead Sponsor
- Hannover Medical School
- Target Recruit Count
- 120
- Registration Number
- NCT01861951
- Locations
- 🇩🇪
University Hospital RWTH Aachen, Medical Dept. IV, Aachen, North Rhine-Westphalia, Germany
🇩🇪University Hospital Cologne, Cologne, North Rhine-Westphalia, Germany
🇩🇪University Medical Centre Mannheim, Surgical oncology, Mannheim, Baden-Wuerttemberg, Germany
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
- Conditions
- Foregut Neuroendocrine TumorHindgut Neuroendocrine TumorMetastatic Digestive System Neuroendocrine Tumor G1Metastatic Neuroendocrine TumorMidgut Neuroendocrine Tumor G1Neuroendocrine Tumor G2Recurrent Digestive System Neuroendocrine Tumor G1Regional Digestive System Neuroendocrine Tumor G1
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: EchocardiographyOther: Laboratory Biomarker AnalysisProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition ScanOther: Placebo AdministrationOther: Quality-of-Life AssessmentProcedure: X-Ray Imaging
- First Posted Date
- 2013-04-26
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 171
- Registration Number
- NCT01841736
- Locations
- 🇺🇸
Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
🇺🇸Alaska Women's Cancer Care, Anchorage, Alaska, United States
🇺🇸Anchorage Oncology Centre, Anchorage, Alaska, United States
A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection
- First Posted Date
- 2013-04-16
- Last Posted Date
- 2018-12-12
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 30
- Registration Number
- NCT01832259
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Pazopanib Maintenance for SCLC
- First Posted Date
- 2013-02-25
- Last Posted Date
- 2019-12-09
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 97
- Registration Number
- NCT01797874
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
- Conditions
- Chromophobe Renal Cell CarcinomaMetastatic Renal Cell CancerPapillary Renal Cell CarcinomaKidney OncocytomaStage IV Renal Cell CancerCarcinoma of the Collecting Ducts of BelliniKidney Medullary CarcinomaRecurrent Renal Cell CarcinomaSarcomatoid Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2013-01-14
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 38
- Registration Number
- NCT01767636
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung
- First Posted Date
- 2013-01-03
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- George Clinical Pty Ltd
- Target Recruit Count
- 12
- Registration Number
- NCT01759303
- Locations
- 🇺🇸
Massachusetts General Hospital/Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2021-05-14
- Lead Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Target Recruit Count
- 43
- Registration Number
- NCT01743482
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Mi, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.